NCT00669019View on ClinicalTrials.gov

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Recurrent MelanomaStage IIA MelanomaStage IIB MelanomaStage IIC MelanomaStage IV Melanoma

Interventions

DRUG

saracatinib

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00669019 - Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter